(redirected from Myelodysplastic syndrome)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for syndrome

Words related to syndrome

References in periodicals archive ?
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008;26:36073613.
Such hypocellularity is consistent with end stage myelodysplastic syndrome.
Prognostic implications of morphology and Karyotype in primary myelodysplastic syndromes. Blood 1986; 67 : 1765-72.
Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients--report of the French society of bone marrow transplantation.
Myelodysplastic syndrome with myelofibrosis: myelodysplastic syndrome as a major primary disorder for acute myelofibrosis.
Expression of p53, MDM2, p21 (waf1), bcl-2, and retinoblastoma gene proteins in myelodysplastic syndrome after autologous bone marrow transplant for lymphoma.
Murakami, "Clinical significance of regulatory T cells in patients with myelodysplastic syndrome," European Journal of Haematology, vol.
Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries.
A Phase 1 dose-escalation trial evaluating the safety and clinical activity of CYAD-02 is planned for early 2020 and will involve a preconditioning chemotherapy (CyFlu) in patients with relapse/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
The patient had a complex medical history: right breast cancer (diagnosed 20 years previously, for which the patient had undergone surgical removal, chemotherapy and hormonal therapy), atrophic gastritis and B12 vitamin deficiency, hepatic cirrhosis due to chronic co-infection with hepatitis B and delta viruses (HBV and HDV) diagnosed 30 years previously, and a myelodysplastic syndrome with excess blasts type 1 (RAEB 1) diagnosed one year previously, for which the patient was undergoing treatment with azacitidine (currently at the second course of treatment).
The same applies to myelodysplasia in which there are a lot of misleading characteristics that may pinpoint to a dysplastic syndrome, but in fact is not a true myelodysplastic syndrome. These conditions that are sometimes misleading can also cause difficulty in diagnosis; therefore, it is imperative that any competent laboratory scientist in microscopic analysis should be able to distinguish these occurrences to provide a timely diagnosis.
Hansen et al., "Immune Mechanisms in Myelodysplastic Syndrome," International Journal of Molecular Sciences, vol.
Arnesen et al., "Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia," British Journal of Haematology, vol.
Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
Kawata et al., "Thrombotic thrombocytopenic purpura associated with myelodysplastic syndrome," International Journal of Hematology, vol.